Sign in Subscribe
BioMed

🧬 BioMed Pulse · 2026-07-23 02:02 UTC

BIOMED PULSE

Daily Briefing on Longevity, Viruses & New Cures

Wednesday, July 23, 2026

⚡ TL;DR

The Ebola Bundibugyo virus outbreak in DRC and Uganda has now surpassed 2,124 confirmed cases and 828 deaths as of July 15, making it the most consequential active PHEIC on the planet right now.

Mood: Cautiously vigilant — the Ebola crisis deepens, the PARTNERS treatment trial is now enrolling, and WHO's new dementia-prevention guidelines offer a rare bright note in longevity science.

🦠 OUTBREAKS & VIRUSES

EBOLA BUNDIBUGYO VIRUS — DRC AND UGANDA (ACTIVE PHEIC)

  • As of July 15, 2026, a cumulative 2,124 confirmed cases and 828 deaths have been reported from DRC, with cross-border transmission ongoing in Uganda. [1]
  • WHO declared a Public Health Emergency of International Concern (PHEIC) on May 22, 2026; the outbreak originated in Mongbwalu Health Zone, Ituri Province, DRC, first alerted May 5, 2026. [2][3]
  • Africa CDC and WHO launched a joint continental response plan on June 5, targeting US$518 million to support African countries in preparedness and response. [4]
  • WHO issued its first comprehensive filovirus clinical management guidelines on June 17, covering all Ebola types and Marburg virus. [5]
  • The PARTNERS clinical trial opened patient enrollment in DRC on July 2, 2026, aiming to identify the first effective treatments specifically for Bundibugyo virus disease. [6]
  • WHO added the first molecular diagnostic test for Bundibugyo virus (BDBV) to its Emergency Use Listing on July 2, enabling rapid genetic-material-based confirmation in blood samples. [7]
  • CDC has mobilized international response and expanded enhanced Ebola airport screening from Washington-Dulles to Atlanta's Hartsfield-Jackson as of May 23, 2026. [8][9]
  • A July 10 CDC statement confirmed the outbreak remains active with no declared end in sight. [10]

ANDES HANTAVIRUS — M/V HONDIUS CRUISE SHIP, MULTI-COUNTRY

  • The fifth WHO Disease Outbreak News posting on this Andes hantavirus (ANDV) cluster was published July 2, 2026, tracking cases originally identified from the cruise ship M/V Hondius after a May 2 notification.
  • Initial WHO reporting from May 4 counted seven cases (two laboratory-confirmed, five suspected) among 147 passengers and crew; subsequent updates confirmed additional cases over following weeks.
  • CDC issued multiple response transcripts through June 24, indicating ongoing monitoring; public risk described as extremely low outside the ship exposure context.

CYCLOSPORIASIS — TACO BELL, UNITED STATES

  • Shredded iceberg lettuce served at Taco Bell locations has been confirmed as the source of Cyclospora infections across five U.S. states, with 1,644 people sick as of July 17, 2026.
  • CDC published a response transcript on July 14, 2026; Cyclospora cayetanensis is a microscopic parasite spread through contaminated food and water.

NIPAH VIRUS — INDIA AND BANGLADESH

  • Kerala State, India confirmed one laboratory-positive Nipah virus (NiV) case in Kozhikode district on June 11, 2026; the adult male developed neurological symptoms on May 30.
  • A separate NiV case was confirmed earlier in Rajshahi Division, Bangladesh, reported to WHO on February 3, 2026, also presenting with fever and neurological symptoms.

WEST NILE VIRUS — UNITED STATES

  • CDC reported an early and record-breaking West Nile virus season as of July 1, 2026, warning Americans ahead of the July 4 holiday weekend to prevent mosquito bites.

MPOX — RECOMBINANT STRAIN, GLOBAL

  • A recombinant monkeypox virus (MPXV) strain combining genomic elements of both Clade Ib and Clade IIb was documented in two cases globally, reported by WHO on February 14, 2026; recombination is a known natural process occurring when two strains co-infect one individual.

E. COLI — FROZEN BLUEBERRIES, UNITED STATES

  • CDC issued a food safety alert on July 7, 2026, warning of an E. coli outbreak linked to recalled frozen blueberries; consumers are advised not to eat the recalled product.

YELLOW FEVER — GLOBAL, AMERICAS

  • From January 1 to May 26, 2026, six countries reported 79 human yellow fever infections; elevated transmission activity in the Americas carried over from a 2025 surge, per WHO DON published June 24, 2026.

WHO PANDEMIC AGREEMENT — PABS NEGOTIATIONS

  • WHO Member States advanced but did not finalize negotiations on the Pathogen Access and Benefit Sharing (PABS) annex of the WHO Pandemic Agreement as of July 18, 2026, a key mechanism for equitable response to future pandemics.

🧬 LONGEVITY & AGING

WHO DEMENTIA PREVENTION GUIDELINES — UP TO 45% OF RISK IS MODIFIABLE

  • WHO released updated guidelines on July 15, 2026, concluding that up to 45% of dementia risk could be prevented or delayed through evidence-based interventions across the life course.
  • The guidelines provide countries with specific recommendations targeting modifiable risk factors including cardiovascular health, education, physical activity, and hearing loss management.

DELIRIUM AS A BRIDGE BETWEEN INFECTION AND DEMENTIA

  • Two commentary pieces in Lancet Healthy Longevity (Sipilä/Kivimäki; Penfold/Jiwaji/MacLullich) propose that delirium following severe infection may be the missing biological link explaining why serious infections accelerate the path to dementia in older adults.

HIGH-DOSE INFLUENZA VACCINE AND OLDER ADULTS

  • A systematic review and meta-analysis published in Lancet Healthy Longevity (Zhao et al.) found high-dose influenza vaccines reduce hospitalization outcomes and mortality in older adults compared to standard-dose formulations.
  • A linked commentary by Icardi and Paolozzi identifies remaining gaps in uptake and access for high-dose formulations in elderly populations.

NAD+ AND BONE REPAIR IN AGING TISSUE

  • A study in Bioactive Materials (Jiang et al., June 2026) describes a senescent-metabolism-modulating hierarchical scaffold that restores NAD+ homeostasis and redox balance, improving aged bone repair in preclinical models.
  • NAD+ depletion is a well-characterized hallmark of cellular aging; this scaffold approach targets that deficit directly at the tissue level.

KAEMPFEROL FROM MORINGA AND LONGEVITY IN DROSOPHILA

  • Research published in Toxicology Reports (Iorjiim et al.) found kaempferol, a flavonoid isolated from Moringa oleifera L., extends lifespan and reverses efavirenz-induced functional senescence in Drosophila melanogaster fruit flies.
  • The finding is notable given concurrent CDC outbreak alerts linking Moringa leaf powder supplements to Salmonella, separating potential biological benefit from the contamination risk of specific commercial products.

RECOMBINANT COLLAGEN XVII AND SKIN PHOTOAGING

  • A study in Annals of Medicine (Wang et al., July 16, 2026) found recombinant human collagen XVII protects epidermal stem cells from blue light-induced photoaging by downregulating the Notch signaling pathway, a key regulator of stem cell fate.

EMERIN, TAU, AND NEURONAL AGING

  • Published in Nucleus (Sohn et al., July 7, 2026), research links the mechanically-sensitive nuclear envelope protein emerin to tau-induced cytoskeletal remodeling in neurons, connecting physical forces at the nuclear level to neurodegeneration biology.

P16-INK4A SENESCENCE BIOMARKER — VALIDATION CONCERN

  • A technical note in Islets (Pipella and Thompson, July 21, 2026) flags critical antibody validation issues for detecting p16-INK4A, a canonical cellular senescence biomarker, in pancreatic tissue by immunohistochemistry, urging researchers to confirm antibody specificity before drawing conclusions.

HYPERTENSION AND FRAILTY IN AGING — INDIA COHORT DATA

  • A letter in Blood Press (Goyal, Kalra, Nagpal, July 7, 2026) discusses associations between hypertension and frailty among middle-aged and older Indian adults from the Longitudinal Ageing Study in India, adding population-level data from a low- and middle-income country context.

PREPARING FOR A DEMENTIA PREVENTION ERA

  • Commentary in Lancet Healthy Longevity (Beeri and Gu) calls for practical, real-world implementation strategies as evidence accumulates that dementia is preventable, arguing that health systems must now prepare infrastructure for population-scale intervention.

💊 NEW CURES & APPROVALS

REVTORPYK (GEDATOLISIB) — CELCUITY INC., ORIGINAL APPROVAL

  • Celcuity Inc. received an original FDA approval (NDA219908) for Revtorpyk, the brand name for gedatolisib, a PI3K/mTOR inhibitor targeting cancer cells via dual pathway blockade.

RETEVMO (SELPERCATINIB) — ELI LILLY AND CO., SUPPLEMENTAL APPROVALS

  • Eli Lilly received two supplemental approvals (NDA213246 and NDA218160) for Retevmo (selpercatinib), a RET kinase inhibitor used in RET-fusion-positive cancers including certain lung and thyroid cancers.

REPATHA (EVOLOCUMAB) — AMGEN INC., SUPPLEMENTAL APPROVAL

  • Amgen received a supplemental approval (BLA125522) for Repatha (evolocumab), a PCSK9 inhibitor that lowers LDL cholesterol by increasing LDL receptor activity; relevant to cardiovascular aging and longevity risk management.

ENLICITIDE — MERCK SHARP AND DOHME LLC, ORIGINAL APPROVAL

  • Merck Sharp and Dohme received an original FDA approval (NDA220848) for enlicitide chloride, a novel oral agent; mechanistic details indicate a new molecular entity for an undisclosed indication.

AFATINIB DIMALEATE GENERICS — HETERO LABS AND APOTEX, ORIGINAL APPROVALS

  • Two generic manufacturers, Hetero Labs Ltd V (ANDA210750) and Apotex (ANDA210725), received original approvals for afatinib dimaleate, an EGFR/HER2 inhibitor used in non-small cell lung cancer, expanding affordable access.

🧪 CLINICAL TRIALS

PSILOCYBIN AND HEALTHY AGING BIOMARKERS — LONG-LIFE STUDY (NCT07719088)

  • The LONG-LIFE trial is a randomized Phase I dose-ranging study enrolling up to 50 adults aged 60 to 80 to evaluate whether psilocybin impacts aging-related biomarkers, cognitive function, and purpose in life in medically stable older adults.

PARTNERS TRIAL — BUNDIBUGYO VIRUS TREATMENTS, DRC

  • Patient enrollment opened July 2, 2026, in DRC for the PARTNERS clinical trial, the first international study to evaluate candidate therapeutics specifically against Bundibugyo virus disease, conducted under WHO coordination. [6]

PET IMAGING OF PDE4 IN ALZHEIMER DISEASE AND MCI (NCT07169630)

  • An NIH study is using PET imaging to measure phosphodiesterase-4 (PDE4) levels, an inflammation-linked enzyme, in adults with Alzheimer disease or mild cognitive impairment, aiming to understand neuroinflammation's role in aging-related brain disorders affecting approximately 5 million U.S. adults.

AMYLOID PET IN THE BALTIMORE LONGITUDINAL STUDY OF AGING (NCT07099053)

  • Researchers are tracking amyloid protein accumulation using imaging scans in participants of the long-running Baltimore Longitudinal Study of Aging to identify early predictors of cognitive decline.

ANTI-TSLPR CAR-T IN REFRACTORY B-CELL ALL (NCT07572136)

  • A NIH trial is testing Anti-CRLF2-R/TSLPR chimeric antigen receptor T cells (TSLPR-CART) in participants with recurrent or refractory CRLF2-R/TSLPR-overexpressing B-cell acute lymphoblastic leukemia, addressing a hard-to-treat mutation-driven cancer subtype.

FALLS AS A MARKER OF PRECLINICAL ALZHEIMER DISEASE (NCT04949529)

  • A longitudinal cohort study (NCT04949529) is examining whether falls and functional mobility changes in cognitively normal individuals can serve as early biomarkers for preclinical Alzheimer disease, probing both central and peripheral mechanisms.

ORFORGLIPRON IN ADOLESCENT OBESITY — LY3502970 (NCT06672939)

  • An Eli Lilly-sponsored study under Master Protocol J4M-MC-PWMP is evaluating the oral GLP-1 receptor agonist orforglipron once daily versus placebo in adolescents with obesity or overweight with comorbidities, with pharmacokinetics and efficacy as primary endpoints.

KETOCONAZOLE FOR MILD AUTONOMOUS CORTISOL SECRETION (NCT07649317)

  • A NIH trial is studying whether ketoconazole can normalize the daily cortisol rhythm in patients with mild autonomous cortisol secretion (MACS), a condition linked to hypertension, diabetes, and weight gain relevant to metabolic aging.

WARNING PROJECT — GERIATRIC CANCER CARE OPTIMIZATION (NCT07704307)

  • A trial testing the WARNING Pack, a multimodal geriatric intervention package providing early detection of geriatric syndromes in older patients with cancer, aims to optimize oncology management in daycare settings.

📢 PUBLIC HEALTH

WHO CANCER PROJECTION — CASES TO NEARLY DOUBLE BY 2050

  • WHO warned on July 8, 2026, that new cancer cases are projected to nearly double by 2050; currently 20.6 million new cases and close to 10 million deaths occur annually, more than 26,000 lives lost per day.

GLOBAL CHILDHOOD IMMUNIZATION — 90% DTP COVERAGE IN 2025

  • WHO and UNICEF reported on July 15, 2026, that 90% of infants globally (approximately 116 million) received at least one DTP vaccine dose in 2025, and 85% completed the full three-dose series, despite ongoing challenges from conflict and hesitancy.

EL SALVADOR ELIMINATES TRACHOMA

  • WHO validated El Salvador as having eliminated trachoma as a public health problem on July 13, 2026; trachoma is the world's leading infectious cause of blindness.

WHO ROAD TRAFFIC DEATHS — 21% DECLINE OVER 14 YEARS

  • Despite adding over one billion motor vehicles globally, the rate of road traffic deaths fell 21% between 2011 and 2025, according to WHO data released July 20, 2026; absolute numbers and disparities by region remain a concern.

CDC DOG IMPORTATION RULES UPDATED

  • CDC clarified and simplified the process for importing dogs from rabies-free and low-risk countries effective July 22, 2026, aiming to prevent re-introduction of dog rabies into the United States.

NEW WORLD SCREWWORM — CDC EMERGENCY OPERATIONS CENTER ACTIVATED

  • CDC activated its Emergency Operations Center in response to a New World screwworm (Cochliomyia hominivorax) threat on June 12, 2026; this parasitic fly larva can infect warm-blooded animals and humans through open wounds.

HEALTHCARE-ASSOCIATED INFECTIONS — DECLINING IN U.S.

  • New CDC data released July 15, 2026, show fewer hospital-acquired infections in 2023, reflecting improved patient safety practices across U.S. healthcare facilities.

UNSAFE FOOD — 866 MILLION ILLNESSES ANNUALLY GLOBALLY

  • WHO estimates released June 3, 2026, place the annual global burden of foodborne illness at 866 million cases and 1.5 million deaths, with children under five facing nearly three times the risk of illness from unsafe food compared to older groups.

This briefing is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personal health decisions.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  2. First meeting of the IHR Emergency Committee regarding the epi… — WHO News
  3. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  4. Africa CDC and WHO launch joint continental Ebola response plan — WHO News
  5. WHO issues comprehensive guidelines on filovirus disease, incl… — WHO News
  6. Patient enrolment begins in a scientific trial to identify the… — WHO News
  7. WHO adds first diagnostic test for Ebola Bundibugyo virus to i… — WHO News
  8. Enhanced Ebola Airport Screening Begins at Washington-Dulles I… — CDC Newsroom
  9. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
  10. CDC Statement on Ebola Outbreak in the Democratic Republic of … — CDC Newsroom

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260723-02-v36 · 2026-07-23 02:02 UTC · pulse.uzylab.com

Read next